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Background and Purpose—Endothelial nitric oxide exerts a variety of protective effects on endothelial cells and blood
vessels, and therefore the nitric oxide synthase 3 gene (NOS3) is a logical candidate gene for stroke susceptibility.
Methods—We used the population-based Stroke Prevention in Young Women case-control study to assess the association
of five NOS3 polymorphisms in 110 cases (46% black) with ischemic stroke and 206 controls (38% black), 15 to 44
years of age. Polymorphisms included 3 single nucleotide polymorphisms (SNPs) in the promoter region (1468 TA,
922 GA, 786 TC), 1 SNP in exon 7 (G894T), and 1 insertion/deletion polymorphism within intron 4.
Results—Significant associations with both the 922 GA and 786 TC SNPs with ischemic stroke were observed in
the black, but not the white, population. This association was attributable to an increased prevalence of the 922 A
allele (OR3.0, 95% CI1.3 to 6.8; P0.005) and the -786 T allele (OR2.9, 95% CI1.3 to 6.4; P0.005) in cases
versus controls. These 2 SNPs were in strong linkage disequilibrium (D1.0), making it impossible to determine,
within the confines of this genetic study, whether 1 or both of these polymorphisms are functionally related to NOS3
expression. Two sets of haplotypes were also identified, 1 of which may confer an increased susceptibility to stroke in
blacks, whereas the other appears to be protective.
Conclusion—Promoter variants in NOS3 may be associated with ischemic stroke susceptibility among young black
women. (Stroke. 2005;36:1848-1853.)
Key Words: genetics  nitric oxide  women and minorities  young, stroke in
Familial aggregation and twin studies provide evidence fora strong genetic component to ischemic stroke risk,
particularly for early-onset cases.1–6 Endothelial nitric oxide
synthase (NOS3) is a logical candidate gene because of its
ability to generate NO, which plays a central role in the
maintenance of vascular homeostasis, including regulation of
the cerebral circulation. NO is also a potent vasodilator7 and
inhibits platelet aggregation.8 Impaired endothelial-mediated
vasodilation is a common feature of many vascular risk
factors, and experimental evidence strongly supports a role
for impaired NO-dependent vasomotor reactivity in the
pathophysiology of stroke.9,10
Association Studies with NOS3 and ischemic stroke have
been conducted exclusively in older populations and typically
included only 1 or a few SNPs genotyped in various ethnic
groups.11–13 These studies have yielded conflicting results. To
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further characterize the role of NOS3 in ischemic stroke, we
evaluated 5 polymorphisms among black and white cases and




The SPYW study is a population-based, case-control study initiated
to examine risk factors for ischemic stroke. Both cases and their
comparison group (controls) were identified from a study area that
included all of Maryland except the far Western panhandle, Wash-
ington DC, and southern portions of both Pennsylvania and Dela-
ware. Cases and controls were recruited between February 26, 1992
and January 1, 1996. Institutional review committees at collaborating
institutions approved the study and participants gave
informed consent.
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The baseline characteristics of the SPYW population are shown in
Table 1. Cases (51 black, 59 white) were women 15 to 44 years of
age with a first cerebral infarction, who were identified by discharge
surveillance at all 59 hospitals in the study area or through direct
referral by regional neurologists. All stroke cases were adjudicated
by 2 neurologists. The methods for discharge surveillance, chart
abstraction, case adjudication, and assignment of probable and
possible underlying causes have been described previously.14,15
Recruitment within 1 year of stroke was required for participation.
Controls (78 black, 128 white) were identified by random-digit
dialing and included women without a history of stroke, frequency
matched by age and geographic region of residence to the cases.
Hypertension, diabetes mellitus, and angina or myocardial infarc-
tion were determined by asking the participant (or her proxy when
the participant was unable to answer) whether she had ever been told
by a physician that she had the condition. Similarly, age, race, and
current smoking status were determined by participant or proxy
report. Total cholesterol was measured according to standard
practice.16
Genotyping of NOS3 Polymorphisms
The 1468 TA, 922 GA, and 786 TC single nucleotide
polymorphisms (SNPs) were genotyped using the MassARRAY
genotyping system (Sequenom, Inc, San Diego, Calif). For the intron
4 tandem repeat, polymerase chain reaction was performed followed
by separation on 2% agarose gels. The exon 7 SNP was genotyped
by polymerase chain reaction followed by restriction fragment length
polymorphism analysis using the enzyme BanII.
Genetic Analysis
Each of the biallelic polymorphisms was analyzed by comparing
differences in genotype frequencies between cases and controls,
stratified by race. 2 tests assuming a recessive model were per-
formed in instances where only a small number of homozygotes
existed for the rare allele. Hardy–Weinberg equilibrium and inter-
marker linkage disequilibrium (LD) was calculated using SnpAna-
lyzer, an enhanced, Web-based version of the SNP-Analysis package
(Kruglyak available at http://www.fhcrc.org/labs/kruglyak/
Downloads). Haplotypes were determined using the PHASE com-
puter program.17
Results
Five polymorphisms in NOS3 were examined (Figure). All
SNPs were in Hardy–Weinberg equilibrium. Using multiple
pair-wise tests, significant LD was observed between four
genotyped polymorphisms in the white population (D0.79
to 1.00). Lower D values were observed between all SNPs
and G894T (D0.41 to 0.76). However, in the black
population, only the promoter SNPs were in LD with each
other (D0.82 to 1.00).
Two promoter SNPs, 922 GA and 786 TC, were
significantly associated with stroke susceptibility in blacks
when compared by genotype and allele (P0.005 to 0.017;
Table 2). The odds ratio for blacks was 3.0 (95% CI, 1.3 to
6.8) with the 922 AA genotype and 2.9 (95% CI, 1.3 to 6.4)
with the 786 TT genotype. This association was indepen-
dent of hypertension status, because stroke susceptibility was
still significantly associated after adjusting for this dichoto-
mous variable (P0.030). No significant associations were
observed with interaction analysis with “current smoking”
status in either population.
Inspection of haplotypes revealed that the same haplotype was
most common in both blacks and whites (TATbG; Table 3). One
haplotype was significantly different between black cases and
controls. This haplotype, AGCaG, was not observed in any cases
but was observed in 8% (n13) of control participants
(P0.001). Further inspection of haplotypes revealed potential
“risk” and “protective” haplotypes, if 1 or 2 SNPs were ignored.
For example, the TATxG haplotype (where x is any allele)
occurred in 59% of the black cases versus 44% of controls
(P0.02). Conversely, the AGCxx haplotype occurred in 10%
of black cases versus 24% of controls (P0.004).
Discussion
NO is an important and well-characterized vasodilator, with
homeostasis of NO essential in maintaining vascular tone in
the systemic and cerebral circulation. We observed signifi-
cant associations with the 922 and 786 promoter SNPs of
the NOS3 gene and susceptibility to stroke in black women.
black women with the risk genotype for either SNP (922
AA or 786 TT) had 3 the risk of stroke compared with
women with the alternative genotypes. This effect was not
observed in the white women.
There is a paucity of comparable data by which to assess
our main finding that black women with the risk genotypes
were at an increased risk of stroke. Two British studies have
examined the association of NOS3 polymorphisms with
stroke in elderly white populations. In an earlier study, the
exon 7 G894T SNP was not found to be associated with a
combined case population of ischemic stroke and transient
ischemic attacks, nor with the degree of carotid stenosis.11 A
subsequent study by the same group found an association
between 786 TC and intron 4 insertion/deletion haplo-
TABLE 1. Clinical Characteristics
Characteristics Cases Controls P
Sample size 110 206
Blacks, no. (%) 51 (46) 79 (38)
Whites, no. (%) 59 (54) 127 (62)
Median age, y 39 38
High blood pressure, % 27 14 0.004
Diabetes, % 15 4 0.0003
High blood cholesterol, % 17 18 NS
Current smoking, % 43 29 0.007
NS indicates not significant.
Genomic structure of the NOS3 gene and polymorphisms geno-
typed. The 26 exons (vertical lines) of NOS3 span 20 kb on
chromosome 7. The locations of the five polymorphisms geno-
typed are shown. The SNPs associated with stroke are boxed.
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types and lacunar infarction in the absence of associated
ischemic leukoaraiosis and a protective effect of the intron 4
“a” allele.12 We did not observe this protective effect in our
sample. Although our allele frequencies for both the single
SNPs and haplotypes are very similar for the overall white
case and control groups, unfortunately, our sample size is too
small to examine stroke subtypes to directly compare studies.
There are several potential explanations for the differing
associations in different populations. First, these differences
could be attributable to chance, although this is unlikely, given
the small probability values and the small number of tested
polymorphisms. Second, population-stratification bias may be
involved. Because our results indicate that blacks have a higher
prevalence of the 922 AA and 786 TT genotypes and an
increased risk of early-onset stroke, these genotypes might be a
marker for African ancestry in general, rather than a marker for
increased stroke susceptibility. Third, the association could be
caused by a polymorphism in LD with a nearby functional
mutation. Finally, NOS3 may contribute causally to the excess
early-onset stroke risk among blacks and not among whites
because of different environmental exposures or different non-
NOS3 genetic backgrounds.
The 2 SNPs associated with stroke in the SPYW popula-
tion are both located in the 5 promoter region of NOS3 and
were in strong LD in both the white and black populations.
Accordingly, we cannot determine whether 1 of these is a true
functional polymorphism. Promoter analysis performed by
others suggests that the 786 SNP may be responsible for a
functional change in NOS3 gene expression.18 The 786 T
allele conveyed a lower level of NOS3 expression than the C
allele in the presence of the intron 4 polymorphic sequence.
Lower levels of NOS3 expression may lead to reduced protective
effects in endothelial cells and thus predispose to stroke.
Haplotype inspection further identified potential risk and
protective haplotypes in blacks. The putative risk haplotype,
TATxG, suggests that the intron 4 polymorphism is not
involved in the effects of NOS3 on stroke susceptibility.
However, it is difficult to determine whether the findings are
attributable to a true haplotype effect or to the strong LD
between the promoter SNPs. The same is true for the
protective haplotype, AGCxx, which is independent of the
intron 4 and exon 7 polymorphisms.
The present study is limited by its relatively small sample
size and by the fact that the cases are heterogeneous in
clinically determined etiology. Importantly, this limitation
could lead to a reduced ability to identify genetic risk factors
but would not account for significant positive associations.
The small sample size precluded assessing the association of
TABLE 2. Analysis of Stroke Susceptibility and NOS3 Genotypes
1468 T/A 922 G/A 786 T/C Intron 4
G894T
(TAsp, GGlu)
Cases Controls Cases Controls Cases Controls Cases Controls Cases Controls
Whites n50 n116 n52 n110 n50 n117 n55 n121 n59 n120
TT:0.42 TT:0.33 AA:0.40 AA:0.36 TT:0.40 TT:0.34 bb:0.75 bb:0.73 GG:0.49 GG:0.47
AT:0.42 AT:0.52 AG:0.42 AG:0.49 CT:0.40 CT:0.50 ab:0.22 ab:0.25 TG:0.39 TG:.042
AA:0.16 AA:0.16 GG:0.17 GG:0.15 CC:0.20 CC:0.15 aa:0.04 aa:0.02 TT:0.12 TT:0.12
Genotype, P value 0.95 0.66 0.54 0.74 0.76
Allele, P value 0.54 0.88 0.84 0.91 0.86
Blacks n50 n76 n49 n75 n50 n75 n46 n67 n50 n78
TT:0.46 TT:0.30 AA:0.80 AA:0.57 TT:0.78 TT:0.56 bb:0.41 bb:0.45 GG:0.08 GG:0.68
AT:0.36 AT:0.46 AG:0.20 AG:0.35 CT:0.22 CT:0.36 ab:0.37 ab:0.45 TG:0.02 TG:0.32




Genotype, P value 0.36 0.0093 0.017 0.12 0.14

















2 AATaG 0.02 0.19 0.18
3 AATbG 0.04 0.04
4 AATcG 0.02
5 AGCaG 0.14 0.13 0.08*
6 AGCaT 0.01
7 AGCbG 0.03 0.03 0.06 0.08
8 AGCbT 0.20 0.23 0.04 0.08
9 TACbG 0.01 0.01
10 TATaG 0.01 0.09 0.04
11 TATbG 0.51 0.48 0.46 0.39
12 TATbT 0.10 0.09 0.06 0.08
13 TATcG 0.04 0.01
14 TGCbG 0.02
n indicates number of haplotypes. *P0.001.
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NOS3 variants stratified by stroke subtypes and limited the
power for detecting interactions with other risk factors.
This study also has several strengths. First, we examined
multiple polymorphisms, as well as estimated haplotypes, in our
population, allowing for a more comprehensive evaluation of the
gene. Second, our study is the first to examine the association of
NOS3 variants with stroke in blacks. Third, this study involved
the use of a young stroke population, which may have enhanced
our ability to detect a genetic contribution to risk.
In conclusion, our study extends prior work showing the
association of NOS3 promoter variants with isolated lacunar
stroke in an elderly white population12 to early onset ischemic
stroke of diverse subtypes among blacks. More comprehen-
sive studies of the association between NOS3 genetic varia-
tion and both functional correlates and stroke risk in larger,
ethnically diverse populations are needed.
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Editorial Comment
Are We in Another Unavoidable ‘Diagnose and Adios’ Era?
None of us in stroke management regret the passage of the
“diagnose and adios” era, humorously criticized earlier. We
know well that opportunities for stroke management are
arising for more definitive studies. A revolution in imaging,
the rush to apply results from clinical trials, and attempts to
shorten the time frame for action are daily practice because
neurologists are interventionists similar to their colleagues in
cardiology and emergency medicine.1 However, with the
pace of accumulated data from leisurely approached genetic
association studies, we confront the issue of hereditary risk
factors.
In this issue of Stroke, Howard et al2 report on a well-
organized, population-based study in 15- to 44-year-old
women. Among the 5 nitric oxide synthase (NOS)3 poly-
morphisms in 110 cases (46% black) with ischemic stroke
and 206 controls (38% black) who were recruited over 4
years, these investigators found that the 922 G/A and 786
T/C polymorphisms may be associated with ischemic stroke
susceptibility among young black women. Although the small
sample size precluded extensive analysis, this study high-
lights the importance of genetic studies of stroke at a young
age in different ethnic groups.
Genetic factors may play a role in cerebral vascular disease
and may act via endothelial dysfunction, predominantly in the
young. NO synthesized by endothelial NOS is a key mediator
of endothelial function, and it could be a candidate gene for
stroke. The NOS3 intron 4ab insertion/deletion genotype, but
not the 786 T/C or the G894T genotype, was reported to be
associated with isolated lacunar infarction in an English
study3 but not a Japanese study.4 The NOS3 exon 7 poly-
morphism (G894T) was reported to not be associated with
stroke and transient ischemic attack or the degree of carotid
stenosis in patients with cerebrovascular disease.5–7 The
aforementioned results show that the association between the
NOS gene and ischemic stroke is controversial and that there
is a possible positive association between the NOS3 intron
4ab insertion/deletion genotype and small-vessel disease in
white populations or a possible negative association in other
ethnicities.
It is known that the etiology of ischemic stroke in the
young is heterogeneous and diverse and that there might be
racial differences.8 Previous reports regarding ischemic
stroke in the young showed that blacks, unlike whites, more
commonly had the stroke subtype of small-vessel occlusion
than large-artery atherosclerosis and that strokes due to other
determined and undetermined causes occurred in more than
half of young stroke patients in most studies.8–11 The finding
that the 922 G/A and 786 T/C polymorphisms may be
associated with ischemic stroke susceptibility among young
black women should be confirmed in a large, international,
cooperative study. The population-based study design of
Howard et al2 yielded important information, but the pheno-
type approach to the study of stroke, as designed by Hassan
et al,3 might provide other useful data. Before international
cooperative studies are organized, several methodologic
problems need to be solved.
We earnestly agree that those studies, which described
lacunar infarcts beyond Fisher’s early observations, had
methodological limitations: sample sizes were generally
small; risk factors were inconsistently defined; and studies
used a variety of classification methods to define ischemic
stroke subtypes.12 Attempts to refine the stroke subtype
classification are worth anticipating.13 However, efforts to
define reproducible subtype classifications of lacunar infarcts
or small-vessel occlusion are mandatory for future gene
association studies.
Next, the study sample size must be carefully calculated. A
small sample size may preclude assessment of any genetic
association by stroke subtype, race, or sex and may limit the
power of detecting interactions among common risk factors
for stroke. Even more, partial digestion might be common in
restriction fragment length polymorphism studies; although
results of 0% for rare alleles might indicate a very low
frequency, they might still exist in the population. Further-
more, conclusions drawn from such “nonexistent” alleles may
be misleading. At present, a large, multiethnic, population-
based study to explore differences in genetics by association
studies might not be feasible because the parameters to
generate hypotheses are lacking. We need more high-quality
genetic descriptions from stroke-prone areas of persons with
early-onset stroke, such as Asia, Russia, and Africa, with
different environmental exposures and different non-NOS3
genetic backgrounds.
We agree that genetics has revolutionized neurologic
research. Ironically, however, it is not known how many
single-nucleotide polymorphisms would be sufficient for
such a project. Genetic studies are time consuming and
costly, not to mention the pricey proteomics methods after-
ward. Genomics might be more appealing for winning grants
at universities, an approach that may be useful to the faculty
to popularize study proposals but that may not have sufficient
power to determine whether a true functional polymorphism
exists, let alone a correlation between the polymorphism and
patient outcomes.
The results of Howard et al, although inconclusive, point
out the many challenges of genetic studies in ethnically
different populations. With more understanding of these
genetic differences that are not yet modifiable, we may be
caught in another unavoidable “diagnose and adios” era.
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Chief, Stroke Section, Department of Neurology
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